BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.
Stocks · News reference
Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $66
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the price target from $40 to $66.
Rapport Therapeutics Q2 EPS $(1.19) Misses $(0.96) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(1.19) per share which missed the analyst consensus estimate of $(0.96) by 23.96 percent. This is a 58.67 percent decrease over losses of $(0.75) per
8-K filing — Rapport Therapeutics, Inc. (RAPP)
Filed: 2026-08-05 AccNo: 0001193125-26-333853 Size: 464 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits